Company News

08/04/2021

Embody Announces $20.5M Funding Round

Embody, Inc., a privately-held medical device company focused on soft tissue healing, announced that it has secured $11.5 million in an oversubscribed equity financing and entered into a debt financing agreement led by Horizon Technology Finance Corporation to provide up to $9 million in term loans, of which an initial $5 million has been funded,

07/22/2021

First Two Patients Dosed in HemoShear Therapeutics Phase 2 Study

HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, dosed the first two patience in the HERO (HElp Reduce Organic Acids) Phase 2 clinical trial of HST5040, an oral small molecule drug being investigated for the treatment of patients with methylmalonic acidemia (MMA) and propionic acidemia (PA). This trial seeks to

07/19/2021

Phlow Corp. Receives HHS Small Business Prime Contractor of the Year Award

The U.S. Department of Health and Human Services (HHS), recently awarded Phlow Corp. the Office of Small and Disadvantaged Business Utilization (OSDBU), Small Business Prime Contractor of the Year Award. Phlow Corp. is a U.S.-based, public benefit corporation committed to solving America’s broken essential medicine supply chain. This award recognizes Phlow for its performance during

07/15/2021

VCU Health Will Anchor Redevelopment of Former Richmond Public Safety Building

As reported online by the Richmond Times Dispatch, VCU Health will anchor a new venture by Capital City Partners in downtown Richmond’s Public Safety Building at 500 N. 10th Street. The conclusion comes four months after the Richmond City Council unanimously agreed to sell the nearly 70-year-old building for $3.5 million. Capital City Partners said

07/14/2021

Serpin Pharma Receives $1.25 M Award by The Virginia Catalyst Fund for COVID-19 Clinical Investigation

Serpin Pharma was selected to receive a $1.25 MM award from The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), for conducting a clinical investigation for the therapeutic role of SP16 drug in mitigating SARS COV2 (COVID-19) progression in hospitalized patients. The Principal Investigator is Serpin Pharma’s collaborator, Dr. Michael Yun

07/12/2021

Governor Northam Grants $3.4 Million to Advance Research Commercialization

Governor Ralph Northam today announced that 34 small technology-focused businesses in Virginia will receive a total of $3.4 million in Commonwealth Commercialization Fund (CCF) grants to commercialize research in an array of sectors, including agricultural and environmental technologies, autonomous systems, clean energy, cybersecurity, data analytics, life sciences, and space and satellites. These awards mark the